NEW YORK – Single-cell assay developer BioSkryb announced Monday an exclusive agreement to license technology from St. Jude Children's Research Hospital that it plans to use in a diagnostic test to detect and define populations of cancer cells during treatment.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.